April 8, 2024
|
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
|
April 4, 2024
|
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
|
April 3, 2024
|
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
April 1, 2024
|
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
March 26, 2024
|
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
March 18, 2024
|
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
|
March 11, 2024
|
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
|
February 26, 2024
|
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
|
February 8, 2024
|
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
|
January 22, 2024
|
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
|